We scan new podcasts and send you the top 5 insights daily.
Testing for undetectable MRD is crucial for guiding time-limited venetoclax regimens but not continuous BTK inhibitor therapy. Continuous covalent BTK inhibitors rarely clear MRD despite delivering six to nine years of progression-free survival, making routine MRD assays pointless during ongoing monotherapy.
The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.
Current fixed-duration CLL regimens are not MRD-guided, so the test result does not alter the treatment plan. While a negative result is prognostically favorable, its main clinical utility is to provide reassurance. A detectable result can cause unnecessary patient anxiety.
Menin inhibitors achieve high rates of MRD-negative remissions. However, the median duration is very short (4-6 months), suggesting current MRD assays may not adequately capture residual disease and that "MRD negativity" is not a reliable predictor of long-term benefit for this drug class.
A forward-thinking strategy for managing patients on continuous BTK inhibitors involves screening for emerging resistance mutations. These mutations have a lead time of about nine months before clinical resistance develops. This provides a window to switch therapies proactively, rather than waiting for clinical progression.
Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.
The CLL17 study revealed a significant difference in undetectable Minimal Residual Disease (UMRD) rates between treatment arms, yet Progression-Free Survival (PFS) curves were not statistically different. This challenges the assumption that UMRD can consistently serve as a direct proxy for long-term survival outcomes in all contexts.
In current CLL practice, a positive MRD result after fixed-duration therapy does not trigger a change in treatment, such as extending therapy. It serves as a prognostic tool to inform the patient and physician about the likely duration of remission and the need for closer monitoring.
A negative Minimal Residual Disease (MRD) result is not a universal surrogate for Progression-Free Survival (PFS). Its predictive power is context-dependent; it's meaningful when comparing similar treatments (e.g., BTKi + BCL2i vs. another BTKi + BCL2i), but less so when comparing entirely different drug classes.
Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.
Clinical trials often mandate indefinite acalabrutinib treatment until progression. However, emerging data suggests Minimal Residual Disease (MRD) status could serve as a biomarker to guide de-escalation. Achieving MRD negativity may allow physicians to safely stop the BTK inhibitor, personalizing treatment duration to reduce toxicity and cost.